|
|
|||
| |||||||||||||||||||||||||||||||||
2-agonists more than 30 years ago revolutionized the treatment of asthma. Until that time, nonselective sympathomimetic agents, such as ephedrine and epinephrine, which stimulate both
- and
-adrenergic receptors and have a very short duration of action, were used to relieve bronchoconstriction. The selective inhaled
2-agonists, such as terbutaline and albuterol, have a longer duration of action (four to six hours), are potent bronchodilators, relieve symptoms rapidly, and protect against the acute bronchoconstriction caused by stimuli such as exercise1 or the inhalation of cold, dry air.2 For these reasons, in most countries inhaled
2-agonists References
This article has been cited by other articles:
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | TERMS OF USE | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved. |